A 2-Dose AERAS-402 Regimen Boosts CD8(+) Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients

Despite the widespread use of BCG, tuberculosis (TB) remains a global threat. Existing vaccine candidates in clinical trials are designed to replace or boost BCG which does not provide satisfying long-term protection. AERAS-402 is a replication-deficient Ad35 vaccine encoding a fusion protein of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivakumaran, Dhanasekaran, Blatner, Gretta, Bakken, Rasmus, Hokey, David, Ritz, Christian, Jenum, Synne, Grewal, Harleen M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231292/
https://www.ncbi.nlm.nih.gov/pubmed/34177914
http://dx.doi.org/10.3389/fimmu.2021.673532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231292/
https://www.ncbi.nlm.nih.gov/pubmed/34177914
http://dx.doi.org/10.3389/fimmu.2021.673532

Ejemplares similares